You are viewing the site in preview mode
Skip to main content
|
Parameters
|
Automatic (n 93)
|
Echo guided (n 98)
|
P value
|
|---|
|
12 months follow up
|
|---|
|
BMI > 30 kg/m2(%)
|
7 (7.5)
|
6 (6.1)
|
0.622
|
|
Plasma glucose (mg/dl)
|
173.5 ± 21.7
|
171.2 ± 20.9
|
0.171
|
|
HbA1c (mmol/mol)
|
52.9 ± 12.1
|
52.3 ± 12.0
|
0.122
|
|
I NYHA class
|
6 (6.4)
|
2 (2.0)
|
0.016*
|
|
II NYHA class
|
45 (48.4)
|
21 (21.4)
|
0.010*
|
|
III NYHA class
|
38 (40.9)
|
66 (67.3)
|
0.001*
|
|
IV NYHA class
|
4 (4.3)
|
10 (10.2)
|
0.021*
|
|
QRS duration
|
121.6 ± 9.6
|
122.9 ± 9.1
|
0.251
|
|
6MWT
|
319.37 ± 26.92
|
227.92 ± 28.19
|
0.005*
|
|
SonR values (g)
|
1.09 ± 0.07
|
/
|
/
|
|
Echocardiographic parameters
|
|
LVEF (%)
|
36 ± 6
|
27 ± 5
|
0.001*
|
|
LVEDd (mm)
|
63 ± 5
|
65 ± 8
|
0.051
|
|
LVESd (mm)
|
35 ± 4
|
38 ± 5
|
0.001*
|
|
LVEDv (ml)
|
165 ± 24
|
178 ± 41
|
0.054
|
|
LVESv (ml)
|
109 ± 12
|
126 ± 18
|
0.001*
|
|
Mitral insufficiency
|
|
+ (%)
|
50 (53.8)
|
31 (31.6)
|
0.040*
|
|
+ + (%)
|
38 (40.9)
|
57 (58.2)
|
0.004*
|
|
+ + + (%)
|
5 (5.4)
|
10 (10.2)
|
0.285
|
|
Biomarkers
|
|
Lymphocytes
|
7.12 ± 1.27
|
8.48 ± 1.18
|
0.001*
|
|
Neutrophiles
|
4.87 ± 1.85
|
5.69 ± 2.31
|
0.001*
|
|
BNP (pg/ml)
|
148.41 ± 16.40
|
197.26 ± 19.12
|
0.001*
|
|
CRP (mg/L)
|
7.24 ± 0.56
|
8.69 ± 0.83
|
0.036*
|
|
IL6 (pg/ml)
|
5.55 ± 0.03
|
6.31 ± 0.03
|
0.011*
|
|
TNFα (pg/ml)
|
5.35 ± 0.02
|
6.31 ± 0.02
|
0.005*
|
|
Study outcomes
|
|
CRTd responders (%)
|
68 (73.1)
|
58 (59.2)
|
0.038*
|
|
Hospital admission for HF worsening (%)
|
12 (16.1)
|
22 (22.4)
|
0.030*
|
|
Cardiac deaths (%)
|
4 (4.3)
|
7 (7.1)
|
0.538
|
|
All cause of deaths (%)
|
7 (7.5)
|
11 (11.2)
|
0.461
|
- BMI, body mass index; BNP, B type natriuretic peptide; CRP, C reactive protein; HbA1c, glycated hemoglobin 1Ac type; IL-6, interleukine 6; LVEDd, left ventricle end diastolic diameter; LVEDv, left ventricle end diastolic volume; LVEF, left ventricle ejection fraction; LVESd, left ventricle end systolic diameter; LVESv, left ventricle end systolic volume; NYHA II, III, New York Heart Association II and III class; SonR, values of SonR signals; TNFα, tumor necrosis factor alpha; 6MWT, 6 min walking test.** is for statistical significant (p < 0.05)
